組換えタンパク質市場：製品、サービス、エンドユーザー、機能別-2024-2030年の世界予測

組換えタンパク質市場規模は2023年に50億5,000万米ドルと推定され、2024年には58億米ドルに達し、CAGR 14.51%で2030年には130億4,000万米ドルに達すると予測されています。

組換えタンパク質は、細菌、酵母、哺乳類細胞などの発現系に改変遺伝子を挿入することにより作成され、目的のタンパク質を高い純度と機能性で生産します。組換えタンパク質は、組換えDNA技術に由来する遺伝子組換えタンパク質の研究、開発、製造、商品化に携わっています。感染症や慢性疾患の流行、新しい治療薬や診断薬に必要なヘルスケア支出の増加、バイオ製薬会社における研究開発投資の増加により、高品質の組換えタンパク質の必要性が高まっています。ゲノミクス技術の急速な進歩や、低分子医薬品よりも生物製剤の採用が増加していることが、組換えタンパク質の採用を増加させています。しかし、生産と維持のコストが高いため、最終用途産業による組換えDNAの使用に悪影響を及ぼす可能性があります。加えて、動物の繁殖や飼料効率向上のための新たな用途、組換えタンパク質開発への多額の投資が、世界中の最終用途部門によるこれらのタンパク質の使用を促進すると予想される要因です。

製品研究目的での接着分子と受容体の重要な利用

接着分子と受容体は、細胞間コミュニケーション、遊走、免疫反応制御に不可欠です。これらは、がん、炎症、感染症を理解するための研究に広く利用されています。成長因子とケモカインは細胞の成長、分化、移動プロセスを制御します。これらは創傷治癒、組織修復、幹細胞研究への応用に不可欠です。免疫応答タンパク質は、感染防御機構や炎症制御を制御する免疫系の重要な構成要素です。研究者は自己免疫疾患やワクチン開発の研究に免疫応答タンパク質を利用しています。キナーゼタンパク質は、細胞分裂、生存、代謝、その他の生物学的プロセスを制御する細胞内シグナル伝達経路において必須です。キナーゼタンパク質は、がん治療や慢性炎症状態の管理のための創薬標的として重要な可能性を秘めています。膜タンパク質は、細胞のシグナル伝達、輸送、接着に重要であり、多くの生理学的プロセスに関与していることから、創薬や薬剤開発に応用されています。組換え代謝酵素は、細胞の代謝とエネルギー産生を調節する生物学的経路において不可欠です。これらは、糖尿病や肥満などの代謝性疾患をターゲットとした創薬に利用されています。制御タンパク質は、遺伝子発現や、アポトーシスや細胞周期の進行などの細胞プロセスを制御します。これらのタンパク質は、がん治療や、制御不能な細胞増殖や分化を伴うその他の疾患に広く用いられています。構造タンパク質は、生物体内の構造的完全性を維持しながら、細胞や組織に機械的支持を与えます。組織工学や再生医療に関連する生物医学研究に応用されています。

サービス発現サービスは、高収率と標的タンパク質の特性との適合性に重点を置いています。

組換えタンパク質のクローニングには、適切な発現ベクターに標的遺伝子を挿入することが含まれ、その結果、宿主細胞でのタンパク質生産を指示する組換えDNA分子が生じる。クローニングサービスに対するニーズベースの選好には、高効率、特異性、異なる生物への適応性が含まれます。発現とは、遺伝子の情報を機能的なタンパク質産物に変換するプロセスを指します。生産性レベル、翻訳後修飾（PTM）との適合性、より高い収率や下流のアプリケーションに必要な純度レベルに対するスケールアップの容易さなど、いくつかの要因が発現系の選択に影響します。精製は、発現されたタンパク質からコンタミを除去し、創薬、診断、研究などの下流の用途に供するために不可欠です。精製サービスに対する要望には、高い選択性、再現性、収率、最小限のサンプルロスなどがあります。クローニングサービスに対する需要は、分子生物学的技術の進歩により、複数のクローンを同時に作製できるようになったため増加しています。発現サービスは、複雑さのレベルが異なる多様なタンパク質に対応するための宿主システムの改良によって進化してきました。精製サービスは、樹脂の化学的性質と装置の進歩によって進歩し続けており、より高いスループットと収率を可能にしています。

エンドユーザー：製薬・バイオ医薬品企業における組換えタンパク質の広範な利用

学術研究機関は、組換えタンパク質技術における革新的で高度な研究の基盤です。これらの研究機関では、構造生物学、機能性研究、創薬、診断の研究に、高品質で信頼性が高く、費用対効果の高い組換えタンパク質を必要としています。製造受託機関（CMO）や研究開発受託機関（CRO）は、組換えタンパク質の生産、アッセイ開発、前臨床試験を専門とするバイオ製薬会社に研究開発や製品開発のアウトソーシングサービスを提供しています。これらの企業は、迅速な納期、競争力のある価格設定、顧客のニーズに合わせたカスタマイズ可能なサービスを重視しています。バイオ医薬品企業は、治療薬や診断薬の開発において、高品質でGMPに準拠した組換えタンパク質を必要としています。これらのエンドユーザー層は、品質、信頼性、費用対効果の高いソリューションを優先します。また、CROやCMOは、納期と多様な顧客に対応するカスタマイズされた製品を優先し、製薬会社やバイオ製薬会社は、厳格な規制遵守と堅牢な製造能力を必要とします。

機能：創薬・医薬品開発における組換えタンパク質の潜在需要

組換えタンパク質は診断に不可欠であり、様々な疾患の検出やモニタリングを容易にします。酵素結合免疫吸着測定法（ELISA）やラテラルフロー免疫測定法は、組換えタンパク質を抗原または抗体として利用し、特定の疾患に関連する特定のバイオマーカーを検出する一般的な診断技術です。組換えタンパク質は、生物製剤、ワクチン、細胞・遺伝子治療薬の創薬や製造に不可欠な役割を果たし、潜在的な治療標的や薬剤候補としての役割を果たします。さらに、特定の疾患経路を標的とするリード化合物を同定するためのハイスループットスクリーニングアッセイを促進します。診断アプリケーションは、主に感度、特異性、迅速性、費用対効果に重点を置いています。対照的に、創薬・薬剤開発では、組換えタンパク質の純度、安定性、拡張性、機能活性が重視されます。

地域別の洞察

組換えタンパク質市場は、先進的な研究施設と高品質な製品を保証する規制を持つ老舗の製薬会社やバイオテクノロジー企業の存在により、南北アメリカで発展しています。さらに、技術の進歩、研究開発（R&D）資金の大幅な増加、慢性疾患の有病率の上昇、個別化医薬品の需要の急増により、南北アメリカでは組換えタンパク質に対するニーズが高まっています。EMEA地域は、これらのタンパク質を使用するために厳格な規制が実施され、製造業者はGMP基準を遵守する必要があるため、組換えタンパク質市場にとって新興国市場です。APAC地域の組換えタンパク質市場は、慢性疾患の蔓延、細胞生物学、生化学、構造・生物物理学的研究における研究活動の増加、効率的なバイオ医薬品へのニーズにより成長しています。さらに、技術的進歩やバイオ医薬品企業と学術機関との共同研究により、研究所のイノベーションを商業的に実行可能な製品に変換する動きが活発化し、世界中の最終用途部門による組換えタンパク質の採用が促進されると予想されます。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは組換えタンパク質市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、組換えタンパク質市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.組換えタンパク質市場の市場規模および予測は？

2.組換えタンパク質市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.組換えタンパク質市場の技術動向と規制枠組みは？

4.組換えタンパク質市場における主要ベンダーの市場シェアは？

5.組換えタンパク質市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 消費者の間でパーソナライズ医療とタンパク質治療薬への注目が高まる
    • 高齢者や子供の間で感染症や慢性疾患の有病率が高い
    • バイオ医薬品およびバイオシミラータンパク質への需要の急増
  • 抑制要因
    • 組換えタンパク質のコストとメンテナンスにかかる時間の問題
  • 機会
    • バイオマーカーの発見への注目が高まり、組み換えタンパク質の開発への投資が急増
    • 動物の繁殖、飼料効率、健康における組み換えタンパク質の潜在能力の高まり
  • 課題
    • 代替製品の入手可能性と生産上のいくつかの問題
• 市場セグメンテーション分析
  • 製品：調査目的での接着分子と受容体の重要な使用
  • サービス：発現サービスは、高収量と標的タンパク質特性との適合性に重点を置いています
  • エンドユーザー：製薬会社やバイオ製薬会社における組換えタンパク質の広範な活用
  • 機能：医薬品の発見と開発における組換えタンパク質の潜在的需要
• 市場動向分析
  • 南北アメリカ全体のヘルスケアインフラと相まって調査費が増加している
  • アジア太平洋地域における慢性疾患の蔓延と医療調査への多額の投資
  • EMEA地域における医薬品製造施設および組み換えタンパク質の規制ガイドラインの拡大。
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 組換えタンパク質市場：製品別

• 接着分子と受容体
• 成長因子とケモカイン
• 免疫応答タンパク質
• キナーゼタンパク質
• 膜タンパク質
• 組み換え代謝酵素
• 調節タンパク質
• 構造タンパク質

第7章 組換えタンパク質市場：サービス別

• クローン
• 表現
• 精製

第8章 組換えタンパク質市場：エンドユーザー別

• 学術調査機関
• 契約調査機関および契約製造機関
• 製薬・バイオ医薬品企業

第9章 組換えタンパク質市場：機能別

• 診断
• 医薬品の発見と開発

第10章 南北アメリカの組換えタンパク質市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の組換えタンパク質市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの組換えタンパク質市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • iToleranceとNorthway Biotechが融合タンパク質の製造契約を締結
  • バイオビアン、フィンランドの製造施設に5,000万ユーロ超を投資
  • フォルティス・ライフサイエンスがインターナショナル・ポイント・オブ・ケアを買収
  • Curia、CHOZNプラットフォームで細胞株開発サービスを拡大
  • フューチャー・フィールズ、組み換えタンパク質生産のためのショウジョウバエの規模拡大に向け1,120万米ドルを調達
  • メルクのバイオ開発センター拡張、フランス、マルティヤック
  • シェナンドーバイオテクノロジー、cGMPの実践に従って製造されたCTGrade組換えタンパク質の拡張範囲を発表
  • 富士フイルム、組換えタンパク質の大手メーカーであるシェナンドー・バイオテクノロジーを買収
  • サーモフィッシャーサイエンティフィックがペプロテックの買収を完了、組換えタンパク質に参入

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. RECOMBINANT PROTEINS MARKET RESEARCH PROCESS
• FIGURE 2. RECOMBINANT PROTEINS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. RECOMBINANT PROTEINS MARKET DYNAMICS
• FIGURE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. RECOMBINANT PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. RECOMBINANT PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RECOMBINANT PROTEINS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ADHESION MOLECULES & RECEPTORS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ADHESION MOLECULES & RECEPTORS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS & CHEMOKINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS & CHEMOKINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMMUNE RESPONSE PROTEINS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMMUNE RESPONSE PROTEINS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY KINASE PROTEINS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY KINASE PROTEINS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MEMBRANE PROTEINS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MEMBRANE PROTEINS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RECOMBINANT METABOLIC ENZYMES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RECOMBINANT METABOLIC ENZYMES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGULATORY PROTEINS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGULATORY PROTEINS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY STRUCTURAL PROTEINS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY STRUCTURAL PROTEINS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CLONING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CLONING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PURIFICATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BIOLOGICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 56. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 57. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 58. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 59. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 60. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 61. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 62. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 63. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 64. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 67. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 68. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 69. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 70. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 71. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 72. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 73. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 74. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 75. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 76. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 77. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 78. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 79. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 80. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 81. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 82. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 83. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 84. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 85. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 86. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 87. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 88. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 89. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 90. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 91. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 92. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 93. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 94. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 95. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 96. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 97. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 98. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 99. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 100. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 101. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 102. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 103. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 104. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 105. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 106. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 107. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 108. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 109. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 110. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 111. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 112. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 113. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 114. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 115. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 116. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 117. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 118. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 119. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 120. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 121. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 122. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 123. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 124. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 125. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 126. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 127. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 128. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 129. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 130. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 131. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 132. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 133. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 134. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 135. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 136. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 137. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 138. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 139. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 140. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 141. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 142. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 143. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 144. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 145. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 146. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 147. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 148. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 149. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 150. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 151. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 152. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 153. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 154. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 155. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 156. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 157. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 158. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 159. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 160. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 161. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 162. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 163. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 164. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 165. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 166. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 167. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 168. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 169. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 170. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 171. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 172. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 173. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 174. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 175. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 176. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 177. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 178. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 179. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 180. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 181. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 182. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 183. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 184. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 185. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 186. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 187. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 188. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 189. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 190. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 191. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 192. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 193. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 194. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 195. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 196. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 197. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 198. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 199. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 200. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 201. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 202. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 203. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 204. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 205. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 206. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 207. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 208. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 209. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 210. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 211. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 212. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 213. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 214. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 215. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 216. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 217. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 218. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 219. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 220. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 221. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 222. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 223. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 224. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 225. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 226. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 227. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 228. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 229. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 230. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 231. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 232. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 233. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 234. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 235. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 236. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 237. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 238. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 239. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 240. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 241. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 242. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 243. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 244. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 245. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 246. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 247. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 248. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 249. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 250. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 253. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 254. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 255. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 256. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 257. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 258. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 259. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 260. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 261. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 262. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 263. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 264. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 265. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 266. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 267. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 268. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 269. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 270. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 271. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 272. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 273. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 274. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 275. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 276. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 277. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 278. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 279. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 280. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 281. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 282. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 283. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 284. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 285. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 286. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 287. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 288. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 289. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 290. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 291. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 292. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 293. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 294. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 295. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 296. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 297. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 298. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 299. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 300. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 301. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 302. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 303. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 304. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 305. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 306. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 307. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 308. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 309. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 310. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 311. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 312. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 313. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 314. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 315. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 316. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 317. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 318. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 319. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 320. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 321. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 322. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 323. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 324. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 325. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 326. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 327. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 328. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 329. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 330. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
• TABLE 331. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2023 (USD MILLION)
• TABLE 332. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2024-2030 (USD MILLION)
• TABLE 333. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 334. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 335. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
• TABLE 336. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
• TABLE 337. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 338. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 339. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
• TABLE 340. NETHERLANDS RECOMBINANT PROTEINS M

[187 Pages Report] The Recombinant Proteins Market size was estimated at USD 5.05 billion in 2023 and expected to reach USD 5.80 billion in 2024, at a CAGR 14.51% to reach USD 13.04 billion by 2030.

The recombinant proteins are created by inserting a modified gene into an expression system such as bacteria, yeast, or mammalian cells, which then produce the desired protein with high purity and functionality. Recombinant proteins involve research, development, manufacturing, and commercialization of genetically engineered proteins derived from recombinant DNA technology. The prevalence of infectious and chronic diseases, increasing healthcare expenditure needed for new therapeutics and diagnostics, and increased R&D investments within biopharmaceutical companies are raising the need for high-quality recombinant proteins. The rapid advancements in genomics technologies and growing adoption of biologics over small-molecule drugs are resulting in increased adoption of recombinant proteins. However, the high cost of production and maintenance may adversely impact the use of recombinant DNA by the end-use industries. In addition, the emerging applications in animal reproduction and to enhance feed efficiency and significant investments in recombinant protein development are the factors expected to encourage the use of these proteins by the end-use sectors worldwide.

Product: Significant use of adhesion molecules & receptors for research purposes

Adhesion molecules and receptors are essential for cell-cell communication, migration, and immune response regulation. They are widely used in research to understand cancer, inflammation, and infection. Growth factors and chemokines regulate cellular growth, differentiation, and migration processes. They are vital for wound healing, tissue repair, and stem cell research applications. Immune response proteins are crucial components of the immune system that regulate infection defense mechanisms and inflammation control. Researchers use the immune response proteins to study autoimmune diseases and vaccine development. Kinase proteins are essential in cellular signal transduction pathways regulating cell division, survival, metabolism, and other biological processes. Kinase proteins possess significant potential as drug targets for cancer treatment and management of chronic inflammatory conditions. Membrane proteins are crucial for cell signaling, transport, and adhesion and have applications in drug discovery and development due to their involvement in numerous physiological processes. Recombinant metabolic enzymes are vital in biological pathways regulating cellular metabolism and energy production. They are used in drug discovery efforts targeting metabolic diseases, such as diabetes or obesity. Regulatory proteins control gene expression or cellular processes such as apoptosis and cell cycle progression. They are extensively used for cancer treatment and other diseases involving uncontrolled cell growth or differentiation. Structural proteins provide mechanical support to cells and tissues while maintaining structural integrity within organisms. They find applications in biomedical research related to tissue engineering or regenerative medicine.

Services: Expression services focus on high yields and compatibility with target protein characteristics

Recombinant protein cloning involves the insertion of a target gene into an appropriate expression vector, resulting in a recombinant DNA molecule that directs protein production in host cells. Need-based preferences for cloning services include high efficiency, specificity, and adaptability to different organisms. Expression refers to the process of translating a gene's information into a functional protein product. Several factors influence the choice of an expression system, such as productivity levels, compatibility with post-translational modifications (PTMs), and ease of scale-up for higher yields or purity levels required for downstream applications. Purification is essential to remove contaminants from the expressed protein and prepare it for downstream applications such as drug discovery, diagnostics, and research. Preferences for purification services include high selectivity, reproducibility, yield, and minimal sample loss. The demand for cloning services has increased due to advancements in molecular biology techniques, enabling the generation of multiple clones simultaneously. Expression services have evolved with improvements in host systems to accommodate diverse proteins with varying complexity levels. Purification services continue progressing with resin chemistry and instrumentation advances, allowing higher throughput and yields.

End-User: Extensive utilization of recombinant proteins in pharmaceutical and biopharmaceutical companies

Academic research institutes are the foundation for innovative and advanced research in recombinant protein technology. These institutes require high-quality, reliable, cost-effective recombinant proteins to study structural biology, functional studies, drug discovery, and diagnostics. Contract manufacturing organizations (CMOs) and contract research organizations (CROs) provide outsourced research and product development services to biopharmaceutical companies specializing in recombinant protein production, assay development, and preclinical testing. They value rapid turnaround times, competitive pricing structures, and customizable offerings tailored to their customer needs. Pharmaceutical biopharmaceutical companies require high-quality, GMP-compliant recombinant proteins for therapeutic and diagnostic product development. These end-user segments prioritize quality, reliability, and cost-effective solutions. Academic research institutes emphasize discovery-driven research application support; biotechnology companies value customization and scalability; CROs and CMOs prioritize turnaround time and customized offerings catering to diverse customers, while pharmaceutical and biopharmaceutical companies require robust manufacturing capabilities with strict regulatory compliance.

Function: Potential demand of recombinant proteins for drug discovery & development

Recombinant proteins are essential in diagnostics, facilitating detection and monitoring of various diseases. Enzyme-linked immunosorbent assays (ELISAs) and lateral flow immunoassays are common diagnostic techniques that utilize recombinant proteins as antigens or antibodies to detect specific biomarkers associated with specific diseases. Recombinant proteins play an indispensable role in drug discovery and production of biologics, vaccines, and cell and gene therapies and serve as potential therapeutic targets or drug candidates themselves. Additionally, they facilitate high throughput screening assays to identify lead compounds targeting specific disease pathways. Diagnostic applications primarily focus on sensitivity, specificity, rapidness, and cost-effectiveness. In contrast, drug discovery & development emphasizes recombinant proteins' purity, stability, scalability, and functional activity.

Regional Insights

The recombinant protein market is evolving in the Americas owing to the presence of well-established pharmaceutical and biotech companies with advanced research facilities and regulations that ensure high-quality products. Additionally, technological advancements, significant increases in funding for research and development (R&D), the rising prevalence of chronic conditions, and a surge in demand for personalized medicines are resulting in an increased need for recombinant protein in the Americas. The EMEA region represents a developing landscape for the recombinant proteins market owing to the stringent regulations implemented to use these proteins and the requirement for manufacturers to adhere to GMP standards. The recombinant proteins market is growing in the APAC region due to the prevalence of chronic diseases, increased research activities in cell biology, biochemistry, structural and biophysical studies, and the need for efficient biopharmaceuticals. Moreover, technological advancements and collaborations between biopharmaceutical companies and academic institutions are expected to increase the translation of laboratory innovations into commercially viable products and boost the adoption of recombinant proteins by the end-use sectors across the globe.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Recombinant Proteins Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Recombinant Proteins Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Recombinant Proteins Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Agilent Technologies, Inc., Bhat Bio-tech India Private Limited, Bio-Rad Laboratories, Inc., Biogen Inc., BioLegend, Inc. by PerkinElmer, Inc., Biologics International Corp, BPS Bioscience, Inc., Bristol-Myers Squibb Company, Creative BioMart Inc., Croyez Bioscience Co., Ltd., Eli Lilly and Company, Enzo Life Sciences, Inc., Fortis Life Sciences LLC, GenScript Biotech Corporation, GeoVax Labs, Inc., Hzymes Biotech, Johnson & Johnson Services, Inc., Laurus Labs Limited, LenioBio GmbH, Lonza Group AG, Marin Biologic Laboratories, Inc., Merck KGaA, Meridian Bioscience, Inc. by SD Biosensor Inc., Miltenyi Biotec B.V. & Co. KG, Novartis AG, ProMab Biotechnologies, Inc., Proteintech Group, Inc., Proteos, Inc., R&D Systems, Inc. by Bio-Techne Corporation, Sanofi S.A., Sartorius AG, Selvita S.A., Sino Biological, Inc., SK bioscience, Takara Bio Inc., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Recombinant Proteins Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Adhesion Molecules & Receptors
  • Growth Factors & Chemokines
  • Immune Response Proteins
  • Kinase Proteins
  • Membrane Proteins
  • Recombinant Metabolic Enzymes
  • Regulatory Proteins
  • Structural Proteins

• Services
  • Cloning
  • Expression
  • Purification

• End-User
  • Academic Research Institutes
  • Contract Research Organizations & Contract Manufacturing Organizations
  • Pharmaceutical & Biopharmaceutical Companies

• Function
  • Diagnostics
  • Drug Discovery & Development
    • Biologics
    • Cell & Gene Therapy
    • Vaccines
• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Recombinant Proteins Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Recombinant Proteins Market?

3. What are the technology trends and regulatory frameworks in the Recombinant Proteins Market?

4. What is the market share of the leading vendors in the Recombinant Proteins Market?

5. Which modes and strategic moves are suitable for entering the Recombinant Proteins Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising focus on personalized medicine & protein therapeutics in the consumers
    • 5.1.1.2. High prevalence of infectious & chronic diseases among geriatric population and children
    • 5.1.1.3. Surging inclination of demand toward biologics and biosimilars proteins
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns regarding time consumption coupled with high costs & maintenance of recombinant protein
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing focus on biomarker discovery and surging investments recombinant protein development
    • 5.1.3.2. Growing potential for recombinant protein in animal reproduction, feed efficiency, and health
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of alternative products and several issues in production
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Significant use of adhesion molecules & receptors for research purposes
  • 5.2.2. Services: Expression services focus on high yields and compatibility with target protein characteristics
  • 5.2.3. End-User: Extensive utilization of recombinant proteins in pharmaceutical and biopharmaceutical companies
  • 5.2.4. Function: Potential demand of recombinant proteins for drug discovery & development
• 5.3. Market Trend Analysis
  • 5.3.1. Increase in research spending coupled with healthcare infrastructure across Americas
  • 5.3.2. Prevalence of chronic diseases and significant investments in medical research in the APAC region
  • 5.3.3. Expanding drug manufacturing facilities and regulatory guidelines for recombinant protein in the EMEA region.
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis

6. Recombinant Proteins Market, by Product

• 6.1. Introduction
• 6.2. Adhesion Molecules & Receptors
• 6.3. Growth Factors & Chemokines
• 6.4. Immune Response Proteins
• 6.5. Kinase Proteins
• 6.6. Membrane Proteins
• 6.7. Recombinant Metabolic Enzymes
• 6.8. Regulatory Proteins
• 6.9. Structural Proteins

7. Recombinant Proteins Market, by Services

• 7.1. Introduction
• 7.2. Cloning
• 7.3. Expression
• 7.4. Purification

8. Recombinant Proteins Market, by End-User

• 8.1. Introduction
• 8.2. Academic Research Institutes
• 8.3. Contract Research Organizations & Contract Manufacturing Organizations
• 8.4. Pharmaceutical & Biopharmaceutical Companies

9. Recombinant Proteins Market, by Function

• 9.1. Introduction
• 9.2. Diagnostics
• 9.3. Drug Discovery & Development

10. Americas Recombinant Proteins Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Recombinant Proteins Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Recombinant Proteins Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein
  • 13.3.2. Biovian Invests Over EUR 50M in Manufacturing Facility in Finland
  • 13.3.3. Fortis Life Sciences acquires International Point of Care
  • 13.3.4. Curia Expands Cell Line Development Offering with CHOZN Platform
  • 13.3.5. Future Fields raises USD 11.2 million to scale up fruit flies for recombinant protein production
  • 13.3.6. Merck's Biodevelopment Centre Expansion, Martillac, France
  • 13.3.7. Shenandoah Biotechnology Introduces Expanded Range of CTGrade Recombinant Proteins Manufactured Following cGMP Practices
  • 13.3.8. Fujifilm to Acquire Shenandoah Biotechnology, Leading Manufacturer of Recombinant Proteins
  • 13.3.9. Thermo Fisher Scientific Completes Acquisition of PeproTech, engaged in Recombinant Proteins

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio